Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cormedix ( (CRMD) ) has issued an update.
On January 5, 2026, CorMedix entered into an amended and restated employment agreement with Chief Executive Officer Joseph Todisco that raised his base salary to $750,000 as of January 1, 2026, increased his target bonus, expanded his eligibility for equity awards, and confirmed his appointment as chairman of the board effective January 8, 2026, alongside enhanced severance protections and post-employment restrictive covenants that further consolidate leadership stability at the company. Also on January 8, 2026, CorMedix reported preliminary unaudited fourth-quarter 2025 net revenue of about $127 million and full-year net revenue of approximately $310 million, with pro forma full-year revenue of roughly $400 million reflecting its Melinta acquisition, adjusted EBITDA of $77–81 million in the fourth quarter, and cash and short-term investments of around $148 million, while highlighting strong DefenCath utilization, looming Medicare reimbursement-driven price pressure in the second half of 2026, and planned Phase 3 readouts for REZZAYO and DefenCath that, together with operational synergies and 2026 revenue and EBITDA guidance, underscore its transition into a diversified anti-infective player with multiple growth levers and meaningful financial scale.
The most recent analyst rating on (CRMD) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Cormedix stock, see the CRMD Stock Forecast page.
Spark’s Take on CRMD Stock
According to Spark, TipRanks’ AI Analyst, CRMD is a Outperform.
CRMD scores well primarily on the TTM financial inflection to strong profitability and free cash flow, reinforced by upbeat earnings-call guidance and strategic progress. Valuation is supportive with a low P/E, while technicals are constructive but show signs of being near overheated levels. The main risks are sustainability of the recent earnings surge, cash conversion versus net income, increased leverage, and post-TDAPA pricing uncertainty.
To see Spark’s full report on CRMD stock, click here.
More about Cormedix
CorMedix Therapeutics (Nasdaq: CRMD) is a biopharmaceutical company focused on developing and commercializing therapeutic products to prevent and treat life-threatening conditions, particularly serious infections. The company is commercializing DefenCath, a catheter lock solution to prevent catheter-related bloodstream infections in adult hemodialysis patients, and, following its August 2025 acquisition of Melinta Therapeutics, now markets a broader anti-infective portfolio including MINOCIN for Injection, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, KIMYRSA, as well as cardiovascular drug TOPROL-XL, while advancing additional clinical studies for DefenCath and REZZAYO in new indications and patient populations.
Average Trading Volume: 2,780,704
Technical Sentiment Signal: Buy
Current Market Cap: $887.2M
For detailed information about CRMD stock, go to TipRanks’ Stock Analysis page.